ACET earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.58. Updated 2026-07-23.
Adicet Bio (ACET) Research Hub
Adicet Bio (ACET) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 9.52 USD (-0.21%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.58, market cap 0.08B. This hub links to the full technical, earnings and options research available for ACET.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 9.52 USD (-0.21%) |
| 52-week range | 7.42 USD – 9.97 USD |
| Trend regime | Range |
| 14-day RSI | 75.3 (Overbought) |
| Trailing P/E | -0.58 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ACET
Covered Call on ACET: how it works, illustrative setup around the real 9.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ACET: how it works, illustrative setup around the real 9.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ACET: how it works, illustrative setup around the real 9.52 USD price, max profit/loss, breakeven and when to use it. Educational.
ACET technical analysis: range, last 9.52 USD, RSI 75.3, 52w range 7.42 USD–9.97 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ACET in?
Adicet Bio (ACET) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ACET in an uptrend or downtrend?
As of 2026-09-11, ACET is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ACET's trailing P/E ratio?
ACET's trailing P/E is -0.58, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does ACET next report earnings?
ACET is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.692 USD.